


Uniseed

Overview and Investments

February 2018



Uniseed Fund-3



Uniseed FUND-3	Research Dollars	Inventions			Start-ups	
	Research Expenditure	Number of Disclosures	New Provisional Patents	Patents Granted	Start-ups created	Number of Start-ups dependent upon licensing/assign
Total Uniseed (4 Unis + CSIRO*)	\$4,427,533,057	437	212	291	23	68
% Total All Research Orgs (n=66)	40.9%	30.5%	47.8%	56.2%	54.8%	38.4%
% Total All Go8 + CSIRO	68.7%	65.4%	72.4%	82.6%	92.1%	73.9%

* CSIRO includes Data61

** Uniseed partner Universities affiliated Research Institutes (e.g. WEHI/UoM) not included.

Source: 2015 National Survey of Research Commercialisation and member data

<http://www.industry.gov.au/innovation/NSRC/Pages/default.aspx>

Uniseed's *Raison d'être*


- To **facilitate commercialisation** of research partner intellectual property
- To **bridge the gap** between research commercialisation and private capital markets
- To operate under the **financial and commercial discipline** of a fund (to not lose money)

\$50m Commercialisation Fund

Commercialisation fund (not a venture fund)

- Generally invests before other VCs will ('bridge the gap')
- Invests in all technology sectors (e.g. not just biotech)
- 20-40 investments vs 5-10 investments
 - Up to \$2.5 million vs \$10 million per investment
- Unique shareholder needs
 - Dedicated to research partners only
- Continuously investing in early stage
 - Open fund structure
 - Constant risk profile
- When the existing fund is fully committed will have a portfolio of investments
 - Seed investments can take a long time to exit (> 10 years)

Where Uniseed Sits








Uniseed is usually the first investor and continues to invest in all subsequent funding rounds.

\$20m Follow-on Fund

- March 2017: Existing research partners Universities of Melbourne, New South Wales, Sydney and Queensland committed \$20 million (\$5million each over next 10 years) to establish a Follow-On Fund.
 - The new fund will be focussed on lower risk, later stage investment rounds in Uniseed investee companies.
- The new funding will provide additional capital to supplement investment from Uniseed's \$50million Commercialisation Fund (Fund-3); the potential for better returns through greater access to capital for investee companies; further strengthen Uniseed's long term deal alignment; and improve the investment to fee ratio for its members.



Investment Team

Peter Devine CEO	John Kurek Investment Manager	Natasha Rawlings Investment Manager	Anthony Musumeci Investment Manager	Brigid Pappin Investment Analyst
				
BSc; PhD; MBA; Grad Dip Appl. Finance; GAICD; FAICD	BSc; PhD; Grad. Dip. Drug Eval. & Pharm Science; GAICD	B.Bus (Marketing)	B.App.Sci (Hons); MBA; PhD; Grad Cert. Res.Comm.	B.Sci (Hons); PhD.
4 Australian start-ups Products to market Start-ups to successful IPO & trade sale exit Centenary Medal	2 Australian biotechs Preclinical & Clinical Drug Development	Experienced Start-Up CEO Extensive corporate marketing, innovation and sales experience	Former Investment Manager Black Sheep Capital Commercial Manager QUT Bluebox & UniQuest	Investment Intern Medicinal Chemist Commercialisation Technology Intern UniQuest & Uniseed

Benefits to Research Partners



Steady and substantial flow
of research income

Leverage of government
grants and external
investment

Balance licensing and spin-
out commercialisation
strategies

Feed aspirations of
entrepreneurial staff


Develop commercialisation skills

Value generated from IP

Revenues to commercialisation
companies


Return on Investment

Leverage (All Funds) (13x)





Leverage (All Funds) (13x)





Investment Partners (~\$443m)

Australian

INNOVATION CAPITAL

International

SBCVC

软银中国资本

NewVenture
Partners LLC



ACT

CRESCENDO
VENTURES

biotech
CAPITAL INVEST TO CREATE

Allen
& Buckeridge

Starfish Ventures

symbiosis
THE BUSINESS OF SCIENCE

YUUWA CAPITAL

MAYFIELD FUND
NOVO

CONDUIT VENTURES
LIMITED

GBS VENTURE PARTNERS

teQstart

Queensland Cardiovascular Group

BioVentures | QIC

COMVENTURES

KALLOY
VENTURES

Westscheme
superannuation

BRANDON CAPITAL
PARTNERS



canaan
partners

Nth POWER
Energy | Vision | Capital

MRCF
MEDICAL RESEARCH COMMERCIALISATION FUND

Kestrel Capital **sciventures.**
growing global businesses

Southern Cross VENTURE PARTNERS

inQbator

AustralianSuper

ANU CONNECT
VENTURES

BlueSky
Alternative Thinking

Spring Ridge
VENTURES

AIR LIQUIDE

BioComm

CLEANTECH
VENTURES

BA
BRISBANE ANGELS

CANOPY
VENTURES

APPLIED
MATERIALS

ACT

AltaPartners

YELLOW BRICK
Capital Advisers (UK) Limited

1/ONE
VENTURES

artesian

melbourneangels

PARKWALK **Martlet**

MOELIS & COMPANY

WrenCapital

>110 Commercial Grants (~\$122m)



Australian Government
Department of Industry



HealthWorkforce
AUSTRALIA



Queensland
Government



COMMERCIALISATION
AUSTRALIA



wellcome^{trust}



R&D Tax
Incentive

A single idea can
transform your
business



Australian Government
Australian Trade Commission



philanthropy




Australian Government
Australian Research Council



National Institutes
of Health



AusIndustryTM
BUILDING BUSINESS - POWERING PRODUCTIVITY



BILL & MELINDA
GATES foundation

Impact:

Patents, Publications, People

- Over 1000 patents have been supported by Uniseed investee companies (over 250 patent families);
- Over 350 people have been employed through the support of Uniseed investee companies, with many of these employed at our partner universities;
- Over 198 journal articles have been published on research projects funded by these companies;
 - Over 4000 citations; Equivalent h-index 35
- Over 950 media releases and news articles have been published on Uniseed investee companies; and
- Over 240 presentations have been made at conferences or industry seminars, or in industry magazines, based on research funded by Uniseed investee companies.

Top 30 Uniseed Company Publications by Citation

204 publications, 4266 citations, h-index 35

Rank	Company	Citations	Impact	Author(s)	Title	Year	Journal/Book	Comp. No.
1	Verva	189	6.31	K. Bozaoglu, D. Segal, K. A. S	Chemerin Is Associated with Metabolic	2009	Journal of Clinical Endocrinology & Metabolism	14
2	Verva	117	8.4	Peters, Anne L., Buschur, El	Euglycemic Diabetic Ketoacidosis: A Pot	2015	Diabetes Care	14
3	Verva	112	8.474	L. Hutley, W. Shurety, F. Ne	Fibroblast growth factor 1 - A key regula	2004	Diabetes	14
4	Pepfactant	98	38.891	A. F. Dexter, A. S. Malcolm	Reversible active switching of the mech	2006	Nature Materials	29
5	Tenasitech	97	5.554	B. Finnigan, K. Jack, K. Cam	Segmented polyurethane nanocomposit	2005	Macromolecules	31
6	BTi	90	3.515	H. Kampwerth, T. Trupke, J.	Advanced luminescence based effective	2008	Applied Physics Letters	30
7	Calibre Biotechnology	87	4.6	P. D. O'leary and R. A. Hugh	Design of potent peptide mimetics of br	2003	Journal of Biological Chemistry	13
8	Velacor	79	3.753	N. M. Corcoran, M. Najdovs	Inorganic selenium retards progression o	2004	Journal of Urology	20
9	Chirogen	72	n/a	J. Beckmann, D. Dakterniek	Asymmetric free-radical reductions med	2006	Handbook of chiral chemicals	5
10	Spinifex	62	59.558	Robert W. Johnson, M.B., B	Postherpetic Neuralgia	2014	The New England Journal of Medicine	23
11	Spinifex	57	39.207	A. S. C. Rice, R. H. Dworkin,	EMA401, an orally administered highly s	2014	Lancet	23
12	Verva	56	4.088	C. H. Widberg, F. S. Newell,	Fibroblast growth factor receptor 1 is a k	2009	American Journal of Physiology-Endocrinolog	14
13	Verva	55	5.48	F. S. Newell, H. Su, H. Torno	Characterization of the transcriptional a	2006	Faseb Journal	14
14	QRxPharma	52	3.169	Y. Sulub, B. Wabuyeale, P. G	Real-time on-line blend uniformity mon	2009	Journal of Pharmaceutical and Biomedical An	16
15	Pepfactant	51	2.613	L. Z. He, A. F. Dexter and A.	Biomolecular engineering at interfaces	2006	Chemical Engineering Science	29
16	Tenasitech	51	1.6	B. Finnigan, D. Martin, P. Ha	Morphology and properties of thermopl	2005	Journal of Applied Polymer Science	31
17	BTi	50	2.185	B. Mitchell, T. Trupke, J. W.	Bulk minority carrier lifetimes and dopin	2011	Journal of Applied Physics	30
18	QRxPharma	46	3.424	Camilleri, M.Drossman, D. A	Emerging treatments in neurogastroent	2014	Neurogastroenterology & Motility	16
19	Spinifex	46	3.218	U. Anand, P. Facer, Y. Yiang	Angiotensin II type 2 receptor (AT(2)R) l	2012	European Journal of Pain	23
20	QRxPharma	45	2.183	Argoff, Charles E.	Recent Management Advances in Acute	2014	Pain Practice	16
21	Pepfactant	44	4.509	A. F. Dexter and A. P. J. Mid	Switchable peptide surfactants with des	2007	Journal of Physical Chemistry C	29
22	Cryptopharma	39	4.12	R. A. Hughes, T. Harris, E. Al	2-methoxyestradiol and analogs as nove	2002	Molecular Pharmacology	10
23	Verva	38	4.544	V. C. Foletta, M. J. Prior, N.	NDRG2, a novel regulator of myoblast pr	2009	Journal of Physiology-London	14
25	Cryptopharma	36	8.193	T. E. Sutherland, M. Schulig	2-methoxyestradiol is an estrogen recep	2005	Clinical Cancer Research	10
26	Myalgen	36	1.409	D. J. Torpy, A. W. Bachmann	Association between chronic fatigue syn	2004	Endocrine Research	1
27	Neurotide	35	2.951	Y. Koda, M. Del Borgo, S. T.	Synthesis and in vitro evaluation of a lib	2008	Bioorganic & Medicinal Chemistry	19
28	Velacor	35	1.318	N. M. Corcoran, D. Martin, B	Sodium selenate specifically activates p	2010	Journal of Clinical Neuroscience	20
29	BTi	33	5.03	B. Mitchell, J. Greulich and	Quantifying the effect of minority carrie	2012	Solar Energy Materials and Solar Cells	30
30	Chirogen	33	2.165	D. Dakternieks, V. T. Perchy	Single enantiomer free-radical chemist	2003	Tetrahedron-Asymmetry	5



Impact: Awards & Recognition

- Vintela - Best Early Stage VC Deal 2005 (AVCAL)
- QRxPharma - New Product Innovation of the Year 2010 (Frost & Sullivan)
- Spinifex (EMA-401) - Named one of the five most promising drugs in Phase 2 trials 2011 (Thomson Reuters).
- Hydrexia - Queensland's Engineering Excellence Awards 2012 (Engineers Australia)
- Smart Sparrow - 2012 Best in Class at Tech23 (Slattery IT)
- TenasiTech - Brisbane Innovation Scorecard 2012 (Deloitte, Brisbane City Council, Queensland Government).
- Spinifex - Emerging Company of the Year 2012 (BioSpectrum Asia)
- Hydrexia - Asia Pacific Company of the Year 2013 (Cleantech Group's Global Cleantech 100 Awards)
- Smart Sparrow - IMS Global Learning Impact Award 2013, Chartered Accountants ANZ Learn Impact Award 2015 & 2016 Tech Pioneers Top 50.
- Fibrotech - Best Early Stage VC Deal 2014 (AVCAL)
- Spinifex - Best Early Stage VC Deal 2015 (AVCAL); J&J Company of the Year 2015; Professor Maree Smith recognised with J&J Industry Leader Award 2015.
- Hatchtech - Best Early Stage VC Deal 2016 (AVCAL).
- Exonate – Exonate is the 'One to Watch' in the Best Investment in Life Sciences, Business Angels Association Investment Awards 2017.



Impact: Drugs Trials in Man

Company	Discovery	Pre Clinical	Phase I	Phase II	Phase III	Registration	Market
hatchtech	★						Human Headlice
spinifex	★						Neuropathic Pain
Verva	★						Diabetes and Liver Disease
Fibrotech	★						Kidney Disease
Otifex	★						Middle Ear Disorders
QUE			★				Hot Flashes in Breast Cancer Patients
OCCURX	★						Diabetic Retinopathy
ENATHERAPEUTICS	★						Respiratory Disease
Exonate	★						Macular Degeneration
MetabloQ	★						Difficult-to-Treat Cancers
KINOXIS	★						Substance use disorders

★ Stage at Uniseed's initial investment



Impact: Products to Market; Industry Engagement



- Surge protection semi-conductor - sold by Bourns Inc.



- Solar cell manufacture – Revenue \$20m+; Applied Materials



- e-Learning - Australian & US university customers



- Plastics and acrylics - commercial collaborations



- Hydrogen storage - Air Liquide as investor & customer



- Food additives - collaboration with major food manufacturer



- Virus-resistant plants - collaboration with agriculture major



- Improved blood tube - collaborations with market leaders



- Probiotic drink - collaborations with Australian retailers & distributors




- Anti-reflective coatings – collaborations with LED manufacturers



- Cardiac rehab mobile health – collaborations with Cardiologists

Impact: Beyond the start-up



What Uniseed Has Achieved

- Distributions + Portfolio Value >> Shareholder Funds Contributed
- External capital committed \$580m (Leverage \$13 per Uniseed \$)
- More capital returned to universities in research funding from Uniseed start-ups than contributed collectively by universities
- 4 trade sale exits
 - Spinifex – pain drug – sale to Novartis International 2015
 - US\$700m deal including US\$200m up-front
 - Fibrotech – fibrosis drug – sale to Shire Pharmaceuticals 2014
 - US\$557m deal including US\$75m up-front
 - Wedgetail/Vintela – IT security – sale to Quest Software Inc 2005
 - AVCAL best early stage deal of year 2005
 - Fultec Semiconductor – surge protection – sale to Bourns Inc 2008
- 3 asset sales
 - Hatchtech – headlice treatment – sale to Dr Reddy's Labs 2015
 - US\$200m deal including \$60 million pre-commercialisation milestones
 - Otifex - Intranasal betahistine – IP sold to Auris Medical AG in 2016
 - Verva - Diabetes and obesity therapies – Asset sale to Reverex Pty Ltd and Naia Pty Ltd 2015
- 1 IPO
 - QRxPharma, May 07 @ \$150m post
 - More than funds invested returned at time of IPO

Exits



Diabetes and obesity therapies – Asset sale to US Biotech company Naia Metabolic Pharmaceuticals



Intranasal betahistine – sold to Auris Medical AG



Headlice Treatment – sold to Dr Reddys Laboratories



Neuropathic pain drug – sold to Novartis International



Fibrosis drug - sold to Shire Pharmaceuticals



IT security software - sold to Quest Software



Surge protection - sold to Bourns Semiconductor



Pain therapeutics - shares sold from listing on ASX



Asset Sales to



Diabetes and obesity therapies

- Status – Phase 2a clinical trial completed
 - Phase 2a clinical trial of insulin sensitizer (VVP808) in diabetic patients with or without metformin medication successfully completed:
 - Statistically-significant reduction in average plasma glucose concentration from baseline after 24 weeks treatment
 - Intellectual property licensed to two biotech companies
 - VVP808 drug IP sold to US Biotech Naia Metabolic Pharmaceuticals

- Co-investors:



- Contact:

Michael Cowley, Reverx Pty Ltd
michael.cowley1@gmail.com
+61 432 866 738





Asset Sale to



A novel Intranasal betahistine treatment of Meniere's Disease and Vestibular Vertigo

- Asset sale agreement with Swiss Biopharmaceutical company Auris Medical AG.
- Second Phase 1 trials to start 2017
 - Formulation development of a nasal spray completed
 - Phase 1a and 1b trials completed in 2015
- Intranasal betahistine showed good tolerance and a significantly higher bioavailability than reported for oral betahistine administration





Asset Sale to



Treatment for human head lice that kills both adult lice and their eggs

- Sale of intellectual property regarding Xygleze human head lice treatment to Dr Reddy's Laboratories
- Circa US\$200 million deal including US\$10 million up-front and US\$50 million pre-commercialisation payments
- Over 80% success rate in Phase 3 studies
- New Drug Application submitted to US FDA






Acquired by



Neuropathic pain drug

- Acquired by Novartis International AG for US\$200m (AU\$7.3m to Uniseed) plus future contingent payments based on developmental/regulatory milestones of over US\$500m (AU\$2.4m to Uniseed to date)
- Novartis responsible for future trials in nerve pain associated with:
 - diabetes (painful diabetic neuropathy);
 - cancer or its treatment with therapeutic agents (e.g. chemotherapy induced peripheral neuropathy);
 - viruses (e.g. postherpetic neuralgia / shingles); and
 - nerve trauma (peripheral nerve injury induced neuropathy).
- AVCAL “Best early stage deal of year 2015”





Acquired by




Drugs that target fibrosis of kidney and other disorders

- Acquired 2014 by Shire Pharmaceuticals for US\$75m (AU\$14m to Uniseed)
- AVCAL “Best early stage deal of year 2014”



Single sign-on security software for enterprise systems

- Formed in 2000 - Spin off from CRC-DSTC in Brisbane
- 2001 - Co-investment - Uniseed with A&B (\$3.3m)
- 2004 - Wedgetail merged with Vintela Inc, a Utah based security company
- 2005 - Acquired by Quest Software Inc., a NASDAQ-listed global company, for US\$75m (Postscript: Quest sold to Dell for \$2.4bn in 2012)
- Substantial return for its founders, staff and foundation investors
 - AVCAL “Best early stage deal of year 2005”





Acquired by



Devices which significantly improve the protection of vital telecommunications equipment from lightning strike and power surges

- Co-Investors: Allen & Buckeridge; Mayfield Ventures (USA); ComVentures (USA); Crescendo Ventures (USA)
- Relocated on US West Coast after US VC investment
- First sales 2008 including 'Top 4' modem customers
- Asset Sale to Bourns Semiconductor Inc. November 2008





Opioid pain drugs

- The company listed on ASX in May 2007
 - largest ever biotech IPO on ASX
- \$1.2 million returned at time of IPO



Portfolio

Drug Development



Other Technologies





Portfolio

Drug Development

Obesity & Diabetes
Verva Pharmaceuticals

Human Headlice
Hatchtech

Pain Therapeutics
Spinifex Pharmaceuticals

Kidney Disease
Fibrotech Therapeutics

Middle Ear Disorders
Otifex Therapeutics

Diabetic Retinopathy
OccuRx

Respiratory Infections
Ena Therapeutics

Macular Degeneration
Exonate

Difficult-to-Treat cancers
MetabloQ

Hot flushes in Breast Cancer
patients
QUE Oncology

Substance use disorders
Kinoxis Therapeutics

Other Technologies

Rapid blood clotting tubes
Q-Sera

Virus resistant plants
Nexgen Plants

Encapsulation of Active
Ingredients
ProGel

Probiotic Drink
PERKii

Hydrogen Storage
Hydrexia

In-line QC for Solar Cells
BT Imaging

Novel Plastics & Acrylics
Tenasitech

Adaptive e-Learning
Smart Sparrow

Anti-Reflective Coatings
Brisbane Materials

Cardiac Rehab Mobile Health
Cardihab

Drug Development



Obesity & diabetes

Human Head Lice

Neuropathic pain drug

Kidney disease

Middle ear Disorders

Diabetic retinopathy

Respiratory Infection

Age-Related Macular Degeneration

Difficult-to-treat cancers

Hot flushes in Breast cancer patients

Substance use disorders

Hatchtech is developing a new treatment for human head lice that kills both adult lice and their eggs

- Status – NDA submitted
 - Phase 2b clinical trial successfully completed under IND with U.S. FDA
 - Phase 3 pivotal studies met primary & secondary end points; efficacy superior to marketed products
 - Ovidical activity confirmed in phase 3 study (100% efficacy)
 - NDA submitted to US FDA
 - Deal with Dr Reddy's Laboratories 2015
 - AVCAL best early stage deal of year 2016

- Co-Investors:



- Contact:

Hugh Alsop, CEO
halsop@hatchtech.com.au
+61 (0)439 080 353





Spinifex is developing a drug for the treatment of neuropathic pain based on a novel target

- Acquired by Novartis International AG for US\$200m + milestone payments
- Phase 2a clinical trials completed
 - Single and repeat dose phase I studies successfully completed
 - Phase 2a study in post herpetic neuralgia completed
 - Statistically significant primary and secondary endpoints achieved
 - Chemotherapy induced peripheral neuropathy open label trial
 - Reduction in spontaneous pain and sensitivity to cold touch

- Co-investors:



- Contact: Tom McCarthy, CEO
Email: tom@molecule2medicine.com
+1 203 321 7130 (USA)



Fibrotech is developing drugs that target the fibrosis of kidney and other disorders.

- Status – Phase 1 clinical trial completed
 - Orally available lead NCE FT-011 selected for development
 - Novel drug target identified
 - Phase 1b trial completed
 - Deal with Shire Pharmaceuticals

- Co-investors:




- Contact:

Darren Kelly, CEO

dkelly@medstv.unimelb.edu.au

+61 (0)416 088 824



OccuRx is developing drugs that treat the cause of blindness in diabetic retinopathy.

- Status – Pre-clinical
 - IP from Fibrotech not acquired by Shire
 - Preclinical lead selection and optimization
 - Novel drug target identified
 - Lead molecules have shown efficacy in animal models using intra-ocular injection
 - Development of a lead candidate (designated OCX63) through formal preclinical pharmacology and toxicology program

BRANDON CAPITAL
PARTNERS

MRCF
MEDICAL RESEARCH COMMERCIALISATION FUND

- Co-investors:

- Contact: Darren Kelly
 dkelly@medstv.unimelb.edu.au
 +61 (0)416 088 824



Ena Therapeutics is developing novel, synthetic Toll-like receptor (TLR) agonists for the prevention and treatment of respiratory infections.

- Status – Preclinical lead selection and optimization
 - Early studies show the TLR agonists are broad-spectrum agents that leverage the innate immune system to prevent respiratory tract viral infections
 - Series A funds will be used to develop a lead compound through preclinical development and a phase I clinical trial

- Co-investors: 

- Contact: Christophe Demaison, CEO
c.demaison@innovac.com



Exonate is developing novel small molecule inhibitors of SRPK1 which regulates splicing of VEGF, as a treatment for wet Age Related Macular Degeneration.

- Status – Preclinical lead selection and optimization
 - Preclinical studies have shown that topical administration SRPK1 inhibitors reach the back of the eye and reduced choroidal neovascularisation in animal models of AMD
 - Awarded £4.9 million from the Wellcome Trust – Seeding Drug Discovery Initiative
 - Funds will be used to develop a lead compound through preclinical development

- Co-investors:





- Contact: Dr Catherine Beech OBE, CEO
Catherine.beech@exonate.com



MetabloQ is developing novel small molecules to treat difficult-to-treat cancers such as triple-negative breast cancer

- Status – Preclinical lead selection and optimization
 - Novel approach involves blocking specific metabolic processes used by cancer cells but not normal cells.
 - New therapies targeting these processes should be better tolerated and result in less side effects than conventional chemotherapeutic treatments.
 - Triple-negative breast cancer patients represent 15% of breast cancer cases diagnosed each year and represent a significant unmet clinical need.

- Co-investors:



- Contact: Dr. Chris Burns, CEO
cburns@metabloqpharma.com



QUE Oncology is developing novel therapies to address hot flashes in breast cancer patients

- Status – Phase 1b clinical trial completed
 - Lead drug Q-122 is being developed for the treatment of hot flashes in women with a history of breast cancer who are receiving anti-estrogen therapy.
 - Hot flashes are very common in breast cancer survivors after treatment as well as because of some adjuvant treatment, such as tamoxifen.
 - Funds will be used to complete a randomized, double-blind, Phase IIa study of Q-122 in breast cancer survivors suffering from severe hot flashes.

- Co-investors:



- Contact:

rcrombie@queoncology.com

M: +61 439 361 331



Kinoxis is developing novel drugs for the treatment of substance use disorders, including alcohol, prescription and illicit drugs.

- Status – Preclinical
 - Lead candidate is a small, orally bioavailable molecule that acts on the oxytocin pathway in the brain
 - Preclinical studies have shown significant efficacy in animal models of addiction
 - Funds will be used to develop the lead compound through preclinical development

• Co-investors:



Family Offices
&
Sophisticated
Investors

- Contact: Hugh Alsop, CEO
hugh.alsop@kinoxistherapeutics.com
 +61 (0)439 080 353



Other Technologies



Q-SERA

Rapid blood clotting tube



Virus resistant plants



Encapsulation of active ingredients



Probiotic drink



In-line QC for solar panels



Hydrogen storage



Adaptive e-Learning



Superior plastics and acrylics



Anti-Reflective Coatings



Cardiac Rehab Mobile Health

Q-Sera is developing a new blood serum collection tube using a clotting agent from snake venom

- Status – proof of concept
 - Initial development has demonstrated rapid clotting of all patient blood types, including patients on anti-coagulants
 - Investment is being used to develop a prototype tube, demonstrate clinical utility and superiority against existing commercial tubes and partner the project
 - Evaluations underway with commercial partners

- Co-investor: 
- Contact: Michael Grant, CEO
michael.grant@q-sera.com
 +61 (0) 477 358 623



Nexgen is developing a technology that disrupts plant viruses and re-instates viral resistance into plants

- Status – proof of concept
 - The technology has application for viruses across a number of economically significant crops including sugarcane, soybean, corn/maize, rice, potato, wheat, cotton & tomato
 - Partnership with Syngenta - a number of virus resistant plant varieties in development

- Co-investor:



- Contact: Brian Ruddle, CEO
brianr@nexgenplants.com
+61 (0)407 169 979



Encapsulating active ingredients for inclusion in foods, cosmetics or pharmaceuticals

- Status – product prototyping and scale-up
 - In certain applications ProGel allows for the first time encapsulated high value additives small enough to remain undetectable by the consumer (improved stability, delivery and taste masking), whilst still being cost effective to the manufacturer of the ingredients
 - License deal with major dairy company around functional active
 - License deal with PERKii Pty Ltd around probiotics

- Co-investor: 

BRISBANE ANGELS
- Contact: Cameron Turner, CEO
c.turner@progel.com.au
+61 (0)437 448 773



Stable probiotics for improved gut health

- Status – product to market and revenue
 - Exclusive license to Progel microgel technology in the field of probiotics
 - \$4M capital raising April 2016
 - Product launch July 2016 (3 flavours)
 - Two new flavours added October 2016
 - Available in over 300 Australian stores including;
 - Woolworths Metro
 - IGA
 - Online store launched November 2016
 - Received \$1.5 million from Queensland Government BDF program



- Co-investor:



- Contact: Matt Kowal CEO
m.kowal@perkii.com.au

BT Imaging is developing an in-line quality control (imaging) technology for photovoltaic cells

- Status – product revenue
 - Sales of R&D and in line tools, with over 50 tools and modules sold
 - Investment from Applied Ventures, USA – venture arm of Applied Materials

- Co-investors:



- Contact: Ian Maxwell, CEO
ian.maxwell@btimaging.com
 +61 (0)414 606 334





Hydrexia is developing a cost effective hydrogen storage alloy

- Status – product revenue
 - First sale of industrial hydrogen storage and delivery unit to Air Liquide
 - Investment from ALIAD (venture arm of Air Liquide) and Southern Cross Renewable Energy Fund (SCREF)
 - Business development activities ongoing

- Co-investors:



软银中国资本



- Contact: Peter Devine: p.devine@uniseed.com





Smart Sparrow is driving the future of online education with its adaptive, intelligent tutoring and e-learning platform

- Status – early customer adoption
 - Over \$30m raised from Series A, B & C investments and grant funding
 - Deployed solution, offered as a service (hosted in the 'cloud') used by large number of US, AU and other universities
 - Significant revenues: Focus on accelerating platform development and uptake in key university accounts

- Co-investors:  
 

- Contact: David Rowe, Commercial Manager
+61 (0)419 226 417
david@smartsparrow.com





Tenasitech is a nanotechnology company developing better plastics and acrylics

- Status – proof of concept in different applications
 - Scaling-up the production of the nanocomposite enhanced additives
 - Demonstrated scratch resistance of acrylic sheets and molded products (PMMA)
 - Technology also applicable to thermopolyurethanes and nylons
 - Joint development projects with commercial partners

- Co-investors:



- Contact: Richard Marshall, CEO
richard@tenasitech.com
+1 (518) 572 8572



Brisbane Materials is an Anti-Reflective coatings solution specialist

- Status
 - proof of concept in different applications demonstrating increased performance and efficiency
 - Low cost coating of metal oxide and metal oxide blends made from liquid precursors at room temperature and atmospheric pressure.
 - First Product: Silicon based anti reflective coating (ARC) applied to optical substrates used in LEDs



• Co-investors:



软银中国资本




• Contact:

Gary H. Wiseman, Ph.D. (CEO)

gwiseman@brismat.com

+1-650-619-5331



SiO₂ AR coating covalently bonded to glass

Cardihab is a Cardiac Rehabilitation Mobile Health technology

- Status
 - Randomised control trial completed, results showed a significant increase in rehabilitation completion rates.
 - Further platform development with industry specialists and end users.

- Co-investors:



- Contact: Gus Taddeo, (CEO)
gus.taddeo@cardihab.com





Disclaimer

Uniseed Management Pty Ltd (Uniseed) is Authorised Representative of UIIT Pty Ltd, a holder of an Australian financial services licence #299900. This license and authority allows Uniseed to:

- Provide general financial product advice only for securities; and
- Deal in securities,
- To wholesale clients only.
- Uniseed will not provide personal financial product advice under any circumstances.
- This means that Uniseed will not take into consideration your particular objectives or financial situation and needs.
- If you require financial product advice that takes into consideration your objectives or financial situation and needs, you should speak with your financial adviser, accountant, stockbroker, lawyer or other professional adviser.
- Only wholesale clients may invest in any company that we present to you. If you are not a wholesale client, then it will not be possible for you to invest in the company.
- As wholesale clients, Uniseed is not required to provide you with a financial services guide.
- We notify you that Uniseed and/or its related parties may have or will have an interest in the companies being presented. As such, Uniseed and/or its related parties may obtain an advantage from your investment.
- Uniseed staff may be remunerated, in part, on the basis of their success in assisting start-up companies to raise funds.